Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

Stock Information for Bion Environmental Technologies Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Bion Environmental Technologies Inc.

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
Context Therapeutics to Participate in Upcoming Investor Conferences
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
Context Therapeutics Reports Full Year 2024 Operating and Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.